Current and emerging pharmacotherapy for emergency management of preeclampsia

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Introduction: Preeclampsia is a disease specific to pregnancy characterised by new onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For fifty years, antihypertensives have been the mainstay of treating preeclampsia, reducing maternal morbidity and mortality. With increased knowledge of the mechanisms underlying the disease has come opportunities for novel therapies that complement antihypertensives by protecting the maternal vasculature. Areas covered: In this review, the authors consider, in detail, the antihypertensives commonly used today in the emergency care of women with severe preeclampsia. They also review less common anti-hypertensive agents and discuss the role of magnesium sulphate in the management of preeclampsia and the prevention of eclampsia. Finally, they explore novel therapeutics for the acute management of preeclampsia. Expert opinion: The rapid control of maternal hypertension will, and must, remain the mainstay of emergency treatment for women with severe preeclampsia. The role of magnesium sulphate as a primary prevention for eclampsia is context dependant and should not displace a focus on correcting blood pressure safely. The exploration of novel adjuvant therapies will likely allow us to prolong pregnancy longer and improve perinatal outcomes safely for the mother.

Original languageEnglish
Pages (from-to)701-712
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number6
DOIs
Publication statusPublished - 13 Apr 2019

Keywords

  • antihypertensives
  • eclampsia
  • mortality
  • Preeclampsia
  • pregnancy

Cite this

@article{08ea1b051abe4041acf9a86492a4d9aa,
title = "Current and emerging pharmacotherapy for emergency management of preeclampsia",
abstract = "Introduction: Preeclampsia is a disease specific to pregnancy characterised by new onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For fifty years, antihypertensives have been the mainstay of treating preeclampsia, reducing maternal morbidity and mortality. With increased knowledge of the mechanisms underlying the disease has come opportunities for novel therapies that complement antihypertensives by protecting the maternal vasculature. Areas covered: In this review, the authors consider, in detail, the antihypertensives commonly used today in the emergency care of women with severe preeclampsia. They also review less common anti-hypertensive agents and discuss the role of magnesium sulphate in the management of preeclampsia and the prevention of eclampsia. Finally, they explore novel therapeutics for the acute management of preeclampsia. Expert opinion: The rapid control of maternal hypertension will, and must, remain the mainstay of emergency treatment for women with severe preeclampsia. The role of magnesium sulphate as a primary prevention for eclampsia is context dependant and should not displace a focus on correcting blood pressure safely. The exploration of novel adjuvant therapies will likely allow us to prolong pregnancy longer and improve perinatal outcomes safely for the mother.",
keywords = "antihypertensives, eclampsia, mortality, Preeclampsia, pregnancy",
author = "Cox, {Annie G.} and Marshall, {Sarah Arwen Emma Madelaine} and Palmer, {Kirsten Rebecca} and Wallace, {Euan Morrison}",
year = "2019",
month = "4",
day = "13",
doi = "10.1080/14656566.2019.1570134",
language = "English",
volume = "20",
pages = "701--712",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor & Francis",
number = "6",

}

Current and emerging pharmacotherapy for emergency management of preeclampsia. / Cox, Annie G.; Marshall, Sarah Arwen Emma Madelaine; Palmer, Kirsten Rebecca; Wallace, Euan Morrison.

In: Expert Opinion on Pharmacotherapy, Vol. 20, No. 6, 13.04.2019, p. 701-712.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Current and emerging pharmacotherapy for emergency management of preeclampsia

AU - Cox, Annie G.

AU - Marshall, Sarah Arwen Emma Madelaine

AU - Palmer, Kirsten Rebecca

AU - Wallace, Euan Morrison

PY - 2019/4/13

Y1 - 2019/4/13

N2 - Introduction: Preeclampsia is a disease specific to pregnancy characterised by new onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For fifty years, antihypertensives have been the mainstay of treating preeclampsia, reducing maternal morbidity and mortality. With increased knowledge of the mechanisms underlying the disease has come opportunities for novel therapies that complement antihypertensives by protecting the maternal vasculature. Areas covered: In this review, the authors consider, in detail, the antihypertensives commonly used today in the emergency care of women with severe preeclampsia. They also review less common anti-hypertensive agents and discuss the role of magnesium sulphate in the management of preeclampsia and the prevention of eclampsia. Finally, they explore novel therapeutics for the acute management of preeclampsia. Expert opinion: The rapid control of maternal hypertension will, and must, remain the mainstay of emergency treatment for women with severe preeclampsia. The role of magnesium sulphate as a primary prevention for eclampsia is context dependant and should not displace a focus on correcting blood pressure safely. The exploration of novel adjuvant therapies will likely allow us to prolong pregnancy longer and improve perinatal outcomes safely for the mother.

AB - Introduction: Preeclampsia is a disease specific to pregnancy characterised by new onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For fifty years, antihypertensives have been the mainstay of treating preeclampsia, reducing maternal morbidity and mortality. With increased knowledge of the mechanisms underlying the disease has come opportunities for novel therapies that complement antihypertensives by protecting the maternal vasculature. Areas covered: In this review, the authors consider, in detail, the antihypertensives commonly used today in the emergency care of women with severe preeclampsia. They also review less common anti-hypertensive agents and discuss the role of magnesium sulphate in the management of preeclampsia and the prevention of eclampsia. Finally, they explore novel therapeutics for the acute management of preeclampsia. Expert opinion: The rapid control of maternal hypertension will, and must, remain the mainstay of emergency treatment for women with severe preeclampsia. The role of magnesium sulphate as a primary prevention for eclampsia is context dependant and should not displace a focus on correcting blood pressure safely. The exploration of novel adjuvant therapies will likely allow us to prolong pregnancy longer and improve perinatal outcomes safely for the mother.

KW - antihypertensives

KW - eclampsia

KW - mortality

KW - Preeclampsia

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85063504483&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1570134

DO - 10.1080/14656566.2019.1570134

M3 - Review Article

VL - 20

SP - 701

EP - 712

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -